iTeos Therapeutics is targeting the tumor microenvironment to enhance the effectiveness of T-cells at eradicating cancer
Immunotherapy stimulates the immune system to eliminate tumors and this approach has been an important breakthrough in cancer treatment. iTeos Therapeutics is leveraging its expertise in tumor immunology, translational medicine and drug discovery to deliver the next wave of immune therapies for the treatment of inflamed (hot) and non-inflamed (cold) tumors.
Building on the pioneering work of the Ludwig Cancer Research (LICR), iTeos is aiming to unlock the full potential of immunotherapy by improving the frequency, depth and duration of response, and by extending therapeutic benefit to more patients.
iTeos has a broad pipeline focused on multiple complementary mechanisms of action including small molecules targeting IDO1, A2A, and STING as well as antibodies directed to TIGIT and Galectin 3. The portfolio includes the next generation of therapies that will unleash the full potential of immuno-oncology, both in inflamed and non-inflamed cancers.